Daewoong hosts first NABOTA training in Latin America

It now sells the product in 12 countries across Latin America, including Brazil, Argentina, Chile and Peru. Over the past three years, NABOTA's South American sales have grown at a compound annual growth rate of 20%, outpacing the global botulinum toxin market. That trajectory matters because the Latin American aesthetic injectables market was valued at $520.3 million in 2025 and is projected to grow at 9.0% annually through 2033, according to Grand View Research figures the company cited.

Argentina alone stands out as a major market. NABOTA became the first Korean botulinum toxin product to win marketing authorization there and sell successfully. The country is expected to record a compound annual growth rate of 9.3% in aesthetic injectables through 2033. That 9.3% rate exceeds the regional average, signaling stronger demand in Argentina than across Latin America as a whole.

The two-day event, themed "Mastering Aesthetics – From Global Insight to Clinical Excellence," brought together seven international speakers from South Korea, Brazil, Argentina and Dubai. Attendees came from Brazil, Argentina, Chile, Ecuador, Peru and Panama. The program emphasized clinical approaches tailored to Latin American patient anatomy and facial expression patterns rather than generic procedure training. Sessions covered NABOTA's protocols, including NABOLIFT and NABOGLOW, which the company describes as differentiated techniques. Speakers presented real-world clinical cases and discussed how to treat both aesthetic and therapeutic conditions, including hyperhidrosis and masseter muscle work.

Live demonstrations included GLOWTOX, a combination approach pairing botulinum toxin with skin boosters to improve overall skin quality. Panel discussions let medical professionals from participating countries exchange views on how botulinum toxin effects vary over time and how doctors can tailor strategies to each patient's needs, examining how treatment approaches can be adapted to different patient characteristics.

Dr. Kyungo Felix Kim, a speaker from Doctors Dermatology Clinic in South Korea, said the event offered "an opportunity to share the latest trends in botulinum toxin treatments in Korea and NABOTA's differentiated techniques, while exchanging clinical perspectives with medical professionals from other countries. He added that he hoped "doctors trained in Korea will help advance the capabilities of medical professionals across Latin America."

Dr. Ada Trindade de Almeida, a dermatologist from Brazil, emphasized that "doctors must tailor botulinum toxin strategies to each patient's characteristics and use precise injection techniques. She shared practical tips during the session aimed at helping physicians develop more individualized approaches for their patients.

The 200 doctors from multiple countries represented the highest turnout among NABOTA Master Class programs involving medical professionals from more than one country, according to the company. Jun Soo Yoon, head of Daewoong Pharmaceutical's NABOTA Business Division, said the company plans to expand its scientific educational programs to reflect regional healthcare environments and work more closely with medical professionals worldwide.

The company did not disclose specific revenue figures for NABOTA in Latin America or globally, nor did it provide details on market share or competitive positioning against other botulinum toxin manufacturers in the region.

Business information, not medical or legal advice. Verify regulatory status at FDA.gov.